Lubefaro et al
1evaluated the efficacy of first-line carboplatin-paclitaxel (CP) or carboplatin-gemcitabine (CG) combinations in 88 advanced triple-negative breast cancer (TNBC) patients. They concluded that CG and CP are effective and well tolerated first-line platinum doublets in advanced TNBC patients and CG could be more effective than CP in patients previous exposed to taxanes despite worse toxicity profile. However, the time interval between neoadjuvant treatment of a taxane regimen and development of metastatic disease was not described. Current literature does not define the exact interval by which taxane resistance is resolved. In the current study, a time interval pattern till time of metastases for patients exposed to previous taxanes (within 1 year, between 1 and 2 years, or more than 2 years) might predict that some patients previously exposed to taxanes might get more benefit from the taxane rechallenge.
- Lobefaro R
- Mariani L
- Peverelli G
- et al.
Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison.
Clin Breast Cancer. 2022; (S1526-8209(22)00286-5Epub ahead of print)https://doi.org/10.1016/j.clbc.2022.12.008
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Breast Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison.Clin Breast Cancer. 2022; (S1526-8209(22)00286-5Epub ahead of print)https://doi.org/10.1016/j.clbc.2022.12.008
Published online: January 25, 2023
Accepted: January 22, 2023
Received: January 15, 2023
© 2023 Elsevier Inc. All rights reserved.